Peripheral Neuropathy News and Research

RSS
Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
Diabetes impairs women’s sex life

Diabetes impairs women’s sex life

Treatments for peripheral neuropathic pain compared

Treatments for peripheral neuropathic pain compared

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

Diabetic women more likely to report low overall sexual satisfaction

Diabetic women more likely to report low overall sexual satisfaction

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

LUMC oncologist presents survival data for brentuximab vedotin at 17th EHA Congress

LUMC oncologist presents survival data for brentuximab vedotin at 17th EHA Congress

Diabetic Neuropathy: An interview with Dr Brian Callaghan

Diabetic Neuropathy: An interview with Dr Brian Callaghan

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

OSA independently linked with DPN in patients with type 2 diabetes mellitus

OSA independently linked with DPN in patients with type 2 diabetes mellitus

Cebix announces data from Ersatta Phase 1 study on type 1 diabetes

Cebix announces data from Ersatta Phase 1 study on type 1 diabetes

New study into pain associated with diabetes

New study into pain associated with diabetes

dSarm/Sarm1 gene promotes axon destruction after injury

dSarm/Sarm1 gene promotes axon destruction after injury

Aeterna Zentaris announces results from perifosine Phase 1 trial on multiple myeloma

Aeterna Zentaris announces results from perifosine Phase 1 trial on multiple myeloma

Three-drug regimen provides rapid, durable responses for multiple myeloma

Three-drug regimen provides rapid, durable responses for multiple myeloma

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

NIH Consortium selects UBM among 11 CoEPEs

NIH Consortium selects UBM among 11 CoEPEs

Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer study

Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer study

Diamyd Medical completes enrollment in NP2 Enkephalin Phase II study for cancer pain

Diamyd Medical completes enrollment in NP2 Enkephalin Phase II study for cancer pain